Literature DB >> 28755290

Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.

Franziska Jönsson1, Florian Kreppel2.   

Abstract

Currently, virus-based vectors, namely derivatives of the adenovirus, are frequently used in a wide variety of ex vivo or local gene therapeutic applications. However, the efficacy of virus-based vectors in systemic applications is presently still extremely limited. Complex interactions of the various vector types with the patient's organism hinder successful vector deployment. Exemplary, here we summarize barriers to systemic application of Adenovirus-based vectors leading either to acute toxic effects or rapid vector neutralization and discuss strategies to overcome these barriers aiming to develop more efficient vector types.

Entities:  

Keywords:  Adenovirus; Shielding; Vector neutralization; Vector-host interaction; Virus-based vector

Mesh：

Year:  2017        PMID： 28755290     DOI： 10.1007/s11262-017-1498-z

Source DB:  PubMed          Journal:  Virus Genes        ISSN： 0920-8569            Impact factor:   2.332


  64 in total

1.  Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential.

Authors:  Akseli Hemminki; Minghui Wang; Tanja Hakkarainen; Renee A Desmond; Jarmo Wahlfors; David T Curiel
Journal:  Cancer Gene Ther       Date:  2003-08       Impact factor: 5.987

2.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Authors:  Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon N Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; Andre Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

3.  Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Virology       Date:  2006-02-28       Impact factor: 3.616

4.  Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides.

Authors:  Sigrid Espenlaub; Andreas Wortmann; Tatjana Engler; Stéphanie Corjon; Stefan Kochanek; Florian Kreppel
Journal:  J Gene Med       Date:  2008-12       Impact factor: 4.565

5.  Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver.

Authors:  Frédéric Vigant; Delphyne Descamps; Betsy Jullienne; Stéphanie Esselin; Elisabeth Connault; Paule Opolon; Thierry Tordjmann; Emmanuelle Vigne; Michel Perricaudet; Karim Benihoud
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

6.  Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.

Authors:  Mohamed A Farrag; Haitham M Amer; Peter Öhlschläger; Maaweya E Hamad; Fahad N Almajhdi
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

7.  Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity.

Authors:  L Krutzke; J M Prill; T Engler; C Q Schmidt; Z Xu; A P Byrnes; T Simmet; F Kreppel
Journal:  J Control Release       Date:  2016-06-11       Impact factor: 9.776

Review 8.  Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide.

Authors:  Florian Kreppel; Stefan Kochanek
Journal:  Mol Ther       Date:  2007-10-02       Impact factor: 11.454

9.  Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components.

Authors:  Vladimir Subr; Libor Kostka; Tom Selby-Milic; Kerry Fisher; Karel Ulbrich; Leonard W Seymour; Robert C Carlisle
Journal:  J Control Release       Date:  2008-12-30       Impact factor: 9.776

10.  Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.

Authors:  Robert C Carlisle; Ying Di; Anna M Cerny; Andreas F-P Sonnen; Robert B Sim; Nicola K Green; Vladimir Subr; Karel Ulbrich; Robert J C Gilbert; Kerry D Fisher; Robert W Finberg; Leonard W Seymour
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113
View more
  10 in total

1.  From Virus to vector to medicine: Foreword by guest editors.

Authors:  Florian Kreppel; Anja Ehrhardt
Journal:  Virus Genes       Date:  2017-10       Impact factor: 2.332

2.  Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial.

Authors:  Suryanarayan Somanathan; Roberto Calcedo; James M Wilson
Journal:  Mol Ther       Date:  2020-02-07       Impact factor: 11.454

3.  Delivery of Anti-IFNAR1 shRNA to Hepatic Cells Decreases IFNAR1 Gene Expression and Improves Adenoviral Transduction and Transgene Expression.

Authors:  J Guerrero-Rodríguez; A Cárdenas-Vargas; G Gutierrez-Silerio; A Sobrevilla-Navarro; B Bastidas-Ramírez; L Hernández-Ortega; C Gurrola-Díaz; L Gasca-Lozano; J Armendáriz-Borunda; A Salazar-Montes
Journal:  Mol Biotechnol       Date:  2021-10-22       Impact factor: 2.695

4.  The superior role of coagulation factor FX over FVII in adenoviral-mediated innate immune induction of the hepatocyte: an in vitro experiment.

Authors:  Saeed Firoozi Ghahestani; Alireza Shiri; Afagh Moattari; Jamal Sarvari; Ali Moahammad Tamaddon; Seyed Younes Hossein
Journal:  Clin Exp Hepatol       Date:  2020-09-30

5.  Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.

Authors:  Sarah L Hulin-Curtis; James A Davies; Rachel Jones; Emma Hudson; Louise Hanna; John D Chester; Alan L Parker
Journal:  Oncotarget       Date:  2018-05-29

6.  A Human In Vitro Model to Study Adenoviral Receptors and Virus Cell Interactions.

Authors:  Raphael L Tsoukas; Wolfram Volkwein; Jian Gao; Maren Schiwon; Nora Bahlmann; Thomas Dittmar; Claudia Hagedorn; Eric Ehrke-Schulz; Wenli Zhang; Armin Baiker; Anja Ehrhardt
Journal:  Cells       Date:  2022-03-01       Impact factor: 6.600

7.  Regulation of the pyruvate metabolism node by monogene and polygene engineering of HEK-293 cells.

Authors:  Li Xie; Junqing Miao; Xiangchao Li; Xiaoping Yi; Ju Chu
Journal:  RSC Adv       Date:  2019-11-07       Impact factor: 4.036

Review 8.  Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.

Authors:  Rebeca Gonzalez-Pastor; Peter S Goedegebuure; David T Curiel
Journal:  Cancer Gene Ther       Date:  2020-09-19       Impact factor: 5.987

9.  Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates.

Authors:  Xuefeng Zhang; Jing Wang; Jing Lu; Rongrong Li; Shuli Zhao
Journal:  Virol J       Date:  2018-07-24       Impact factor: 4.099

10.  Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications.

Authors:  Sarah L Hulin-Curtis; James A Davies; Davor Nestić; Emily A Bates; Alexander T Baker; Tabitha G Cunliffe; Dragomira Majhen; John D Chester; Alan L Parker
Journal:  Cancer Gene Ther       Date:  2020-01-06       Impact factor: 5.987
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.